A Study of PLB-002 in Advanced Solid Tumors

Required: CLDN6 positive staining by immunohistochemistry

Part 2: Positive CLDN6 staining of tumor tissue (archived or fresh) by IHC tested in the central laboratory

Must have received: standard-of-care therapy

who have failed or intolerant to available standard-of-care therapy or no standard treatment exists

Cannot have received: systemic chemotherapy

Patient received systemic chemotherapy...within 2 weeks prior to start of study drug

Cannot have received: small molecular target therapy

Patient received...small molecular target therapy...within 2 weeks prior to start of study drug

Cannot have received: hormone therapy

Patient received...hormone therapy...within 2 weeks prior to start of study drug

Cannot have received: herbal medication with anti-cancer indication

Patient received...herbal medication with anti-cancer indication within 2 weeks prior to start of study drug

Cannot have received: biological anti-cancer products (such as antibody, antibody-drug conjugate [ADC])

received biological anti-cancer products (such as antibody, antibody-drug conjugate [ADC]) within 4 weeks or 5 half-life time prior to start of study drug (whichever is shorter)

Cannot have received: cytotoxic agents with major delayed toxicity (such as nitrosourea or mitomycin C) (nitrosourea, mitomycin C)

For cytotoxic agents with major delayed toxicity (such as nitrosourea or mitomycin C), 6 weeks of washout are mandated

Cannot have received: anti-cancer therapies targeting at CLDN6

Patient has received any other anti-cancer therapies targeting at CLDN6